Peptide Lab HQ Research Guide
ARA-290
A research-focused compound profile covering ARA-290 identity, Cibinetide research, innate repair receptor signaling, small-fiber neuropathy models, concentration reference, reconstitution reference, and safety considerations.
Compound Data
Compound Profile
| Compound Name | ARA-290 |
|---|---|
| Synonyms | Cibinetide, PHBSP, pyroglutamate helix B surface peptide, helix B surface peptide |
| Compound Type | Erythropoietin-derived non-hematopoietic peptide |
| CAS Number | 1208243-50-8 |
| PubChem CID | 91810664 |
| Amino Acid Length | 11 amino acids |
| Amino Acid Sequence | pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser |
| Short Sequence | ZEQLERALNSS |
| Molecular Formula | C₅₁H₈₄N₁₆O₂₁ |
| Molecular Weight | Approximately 1257.3 g/mol |
| Research Category | Innate repair receptor, EPOR/CD131, small-fiber neuropathy, neuroprotection, inflammation, and tissue-protection research |
| Appearance | White to off-white lyophilized powder |
| Use | For laboratory research use only. |
Research Applications
Key Research Applications
ARA-290 is commonly discussed in controlled research models involving innate repair receptor signaling, EPOR/CD131 pathway activity, small-fiber neuropathy, neuroprotection, anti-inflammatory signaling, and tissue-protective response pathways.
Innate Repair Receptor Research
ARA-290 is commonly studied around tissue-protective receptor signaling involving EPOR and CD131 pathway context.
Small-Fiber Neuropathy Models
Cibinetide has been evaluated in sarcoidosis-associated small-fiber neuropathy research involving neuropathic symptoms and nerve-fiber related endpoints.
Neuroprotection Research
ARA-290 appears in neuroprotection research involving nerve injury, retinal models, CNS injury models, and neuronal survival signaling.
Inflammatory Pathway Models
Used in research contexts involving inflammatory signaling, cytokine response, immune-cell function, and tissue-injury resolution.
Tissue-Protection Studies
Commonly discussed in models involving tissue repair, cytoprotection, anti-apoptotic signaling, fibrosis, and injury-response pathways.
Metabolic / Aging Research
ARA-290 has been evaluated in animal research involving inflammation, fibrosis, cardiac aging, insulin-resistance context, and healthspan-related markers.
Research Scope
These applications are provided for educational and research-reference purposes only. Research outcomes may vary based on model type, route, timing, purity, concentration, formulation, and laboratory conditions.
Research Applications
Key Research Applications
ARA-290 is commonly discussed in controlled research models involving innate repair receptor signaling, EPOR/CD131 pathway activity, small-fiber neuropathy, neuroprotection, anti-inflammatory signaling, and tissue-protective response pathways.
Innate Repair Receptor Research
ARA-290 is commonly studied around tissue-protective receptor signaling involving EPOR and CD131 pathway context.
Small-Fiber Neuropathy Models
Cibinetide has been evaluated in sarcoidosis-associated small-fiber neuropathy research involving neuropathic symptoms and nerve-fiber related endpoints.
Neuroprotection Research
ARA-290 appears in neuroprotection research involving nerve injury, retinal models, CNS injury models, and neuronal survival signaling.
Inflammatory Pathway Models
Used in research contexts involving inflammatory signaling, cytokine response, immune-cell function, and tissue-injury resolution.
Tissue-Protection Studies
Commonly discussed in models involving tissue repair, cytoprotection, anti-apoptotic signaling, fibrosis, and injury-response pathways.
Metabolic / Aging Research
ARA-290 has been evaluated in animal research involving inflammation, fibrosis, cardiac aging, insulin-resistance context, and healthspan-related markers.
Research Scope
These applications are provided for educational and research-reference purposes only. Research outcomes may vary based on model type, route, timing, purity, concentration, formulation, and laboratory conditions.
Reference Only
Reconstitution / Research Dosing Reference
Select Reference Vial
Select a vial size to update the concentration, U-100 unit references, and frequency table below.
Quick Reference Summary
| Reference Vial | 10 mg ARA-290 |
|---|---|
| Primary Solution Volume | 1.0 mL bacteriostatic water |
| Primary Concentration | 10 mg/mL |
| Measurement Reference | On a U-100 syringe, 1 unit = 0.01 mL. |
| Amount per U-100 Unit | At 10 mg/mL, 1 unit equals 0.1 mg / 100 mcg ARA-290. |
| Storage Reference | Refrigerate at 2–8°C / 35.6–46.4°F after reconstitution, protected from direct light, unless supplier documentation specifies otherwise. |
Reconstitution Steps
- Draw 1.0 mL bacteriostatic water using a sterile syringe for the selected vial reference.
- Slowly add the BAC water down the side of the vial wall.
- Gently roll or swirl the vial until the material is completely dissolved. The solution should appear clear to slightly hazy depending on concentration and supplier format. Do not shake!
- Because the 10 mg and 16 mg vial references use different solution volumes, verify the selected vial size before recording the final preparation details.
- Label with compound name, vial amount, concentration, solvent volume, preparation date, storage conditions, and handling notes.
- Store refrigerated at 2–8°C / 35.6–46.4°F, protected from direct light, unless supplier documentation specifies otherwise.
Published Research Context
| Reference Type | Reported Amount / Context | Research Notes |
|---|---|---|
| Compound Identity Reference | ARA-290, also referenced as cibinetide / pyroglutamate helix B surface peptide | ARA-290 is commonly discussed as an 11-amino-acid erythropoietin-derived peptide engineered for tissue-protective research without erythropoietic activity. |
| Sequence Reference | Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH / XEQLERALNSS | Sequence, molecular weight, salt form, and terminal modifications should be verified against the supplier COA, batch record, or formula record. |
| Innate Repair Receptor Context | EPOR / β-common receptor heterocomplex research context | ARA-290 is commonly discussed in relation to the innate repair receptor, also described in research as an EPOR and β-common receptor-associated tissue-protective signaling complex. |
| Non-Erythropoietic EPO-Derived Peptide Context | Tissue-protective signaling without erythropoietic effect context | Research discussions commonly distinguish ARA-290 from erythropoietin by describing tissue-protective, anti-inflammatory, and repair-associated signaling without red-blood-cell-stimulating effects. |
| Neuropathy / Neuroprotection Research | Neuropathic-pain, microglia, and neural-injury model context | Published research discussions include neuropathic-pain models, small-fiber neuropathy context, spinal microglia response, neuroinflammation markers, and neuroprotective observations. |
| Inflammation / Tissue-Repair Research | Anti-inflammatory and tissue-protective marker context | ARA-290 research discussions commonly include inflammatory-marker response, wound-healing models, tissue repair, ischemia-reperfusion context, fibrosis markers, and injury-response observations. |
| Cardiometabolic / Organ Protection Context | Cardiac, renal, vascular, and metabolic-stress model context | Research discussions have included cardiac inflammation, fibrosis, renal injury models, vascular function, diabetic wound-healing models, and tissue stress-response endpoints. |
| Public Protocol-Style Reference | Microgram-to-milligram reference examples | Public protocol-style references may describe ARA-290 in microgram-to-milligram examples depending on preparation format, model type, and supplier concentration. These are not clinical dosing standards. |
| Clinical / Research-Chemical Status | No universal research-chemical protocol established | Published study references, clinical-study contexts, public protocol-style references, or wellness protocols should not be treated as dosing instructions for research-chemical vial formats. |
Concentration Reference
| Vial Amount | Solution Volume | Final Concentration |
|---|---|---|
| 10 mg | 1.0 mL | 10 mg/mL |
| 16 mg | 2.0 mL | 8 mg/mL |
Research Dosing Amount / Volume Reference
| Reference Amount | Volume at 10 mg/mL | U-100 Unit Reference | Approx. References per 10 mg Vial |
|---|---|---|---|
| 50 mcg | 0.005 mL | 0.5 units | 200 |
| 0.1 mg / 100 mcg | 0.01 mL | 1 unit | 100 |
| 0.25 mg / 250 mcg | 0.025 mL | 2.5 units | 40 |
| 0.5 mg / 500 mcg | 0.05 mL | 5 units | 20 |
| 1 mg / 1000 mcg | 0.10 mL | 10 units | 10 |
| 2 mg / 2000 mcg | 0.20 mL | 20 units | 5 |
| 5 mg / 5000 mcg | 0.50 mL | 50 units | 2 |
| 10 mg / 10000 mcg | 1.00 mL | 100 units | 1 |
| 16 mg / 16000 mcg | 1.60 mL | 160 units | 0.6 |
Research Frequency / Amount Reference
| Research Window | Frequency | Reference Amount | Units / Volume Reference |
|---|---|---|---|
| Lower Microgram Reference | Calculation reference only | 50 mcg reference amount | 0.5 units / 0.005 mL |
| Standard Microgram Reference | Calculation reference only | 0.1 mg reference amount | 1 unit / 0.01 mL |
| Low Milligram Conversion Example | Public protocol-style reference, not a clinical dosing standard | 250 mcg reference amount | 2.5 units / 0.025 mL |
| Mid-Range Conversion Example | Public protocol-style reference, not a clinical dosing standard | 0.5 mg reference amount | 5 units / 0.05 mL |
| Upper Conversion Example | Calculation reference only | 1 mg reference amount | 10 units / 0.10 mL |
| 2 mg Preparation Reference | Preparation-level calculation reference | 2 mg reference amount | 20 units / 0.20 mL |
| 5 mg Preparation Reference | Preparation-level calculation reference | 5 mg reference amount | 50 units / 0.50 mL |
| 10 mg Preparation Reference | Preparation-level calculation reference | 10 mg reference amount | 100 units / 1.00 mL |
| 16 mg Preparation Reference | Preparation-level calculation reference | 16 mg reference amount | 160 units / 1.60 mL |
Common Research Windows
| Reference Window | Common Length | Research Notes |
|---|---|---|
| Cell-Culture / Innate Repair Marker Window | 24–72 hours | May be used for receptor-pathway response, inflammatory-marker tracking, cellular-stress markers, tissue-protection markers, or peptide-response documentation depending on the model. |
| Acute Tissue-Protection Observation Window | Single session to several days | Used for short-term inflammatory-marker comparison, neuroinflammation marker tracking, injury-response observations, or early pathway documentation depending on the research design. |
| Short Research Window | 1–2 weeks | May be used for early controlled observation involving neuropathy markers, inflammatory markers, tissue-repair markers, or stress-response endpoints. |
| Standard Protocol-Style Window | 2–4 weeks | Commonly used in public protocol-style references for structured observation and comparison across baseline and follow-up periods. |
| Extended Observation Window | 4–12 weeks | Used when longer documentation is needed for neuropathy-marker trends, tissue-repair marker comparison, inflammation-marker tracking, cardiac-marker observations, or follow-up marker documentation. |
| Follow-Up / Washout | 2–8 weeks | Used to document post-study observations, marker return, delayed response patterns, tissue-repair marker changes, or follow-up data depending on the research model. |
Research Note: These tables are provided for educational, research-planning, concentration, frequency-reference, and volume-reference purposes only. ARA-290, also referenced as cibinetide or pyroglutamate helix B surface peptide, is commonly discussed in erythropoietin-derived peptide, non-erythropoietic tissue-protective, innate repair receptor, EPOR / β-common receptor, neuropathy, neuroinflammation, tissue-repair, wound-healing, ischemia-reperfusion, cardiac-marker, renal-marker, and inflammatory-marker research contexts. The selector above updates calculations for a 10 mg vial reconstituted with 1.0 mL bacteriostatic water and a 16 mg vial reconstituted with 2.0 mL bacteriostatic water. Sequence, molecular weight, salt form, solubility, storage, and handling conditions should be verified against the supplier COA, batch record, or formula record when available. Published study references, clinical-study contexts, public protocol-style references, or wellness protocols are not universal research-chemical dosing standards and should not be treated as dosing instructions for research-chemical vial formats. This information is not medical advice, dosing instruction, injectable-use guidance, or a recommendation for human or animal use.
Research Notes
Research Findings & Safety Notes
Research Findings
ARA-290 is commonly discussed in research involving innate repair receptor signaling, EPOR/CD131 pathway activity, small-fiber neuropathy, neuroprotection, anti-inflammatory signaling, tissue repair, fibrosis, and injury-response models.
Study Limitations
ARA-290 research includes clinical studies, animal models, and mechanistic investigations. Findings should be interpreted according to route, formulation, study design, population, and endpoint selection.
Safety Considerations
Laboratory handling should include appropriate PPE, clean technique, proper labeling, batch documentation, and qualified research procedures. Clinical-study references should not be treated as universal research-chemical protocols.
Use Restriction
Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease when discussed as a research-use material.
Related Supplies
Research Supplies
For research supplies, visit our affiliate partner and use code PLHQ10 to save 10% on your order.
Bacteriostatic Water
Commonly referenced in laboratory preparation workflows.
Research Syringes
Supply category for controlled laboratory research preparation.
Prep Supplies
Supporting supplies for clean handling, preparation, and documentation.
Lab Handling
Handling & Storage
Storage
Store materials according to product-specific requirements. Protect from excessive heat, moisture, and direct light.
After Reconstitution
Keep refrigerated after reconstitution unless otherwise specified by the product documentation.
Handling
Use appropriate laboratory PPE, clean handling practices, and qualified research procedures.
Documentation
Maintain batch details, COA records, preparation notes, and internal research documentation.